FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983391421> ?p ?o ?g. }

• W1983391421 endingPage "603" @default.
• W1983391421 startingPage "598" @default.
• W1983391421 abstract "The objective of this study was to retrospectively investigate clinical outcomes of combined immunotherapy with interferon-alpha (IFN-alpha) and low-dose interleukin-2 (IL-2) in Japanese patients with metastatic renal cell carcinoma (RCC). This study included a total of 52 patients with metastatic RCC who were treated by combined immunotherapy with IFN-alpha and low-dose IL-2 following radical nephrectomy. These patients received a subcutaneous injection of IFN-alpha (5 to 6 million U/d) three times per week and intravenous injection of IL-2 (1.4 million U/d) twice per week. Tumor response was evaluated every 16 weeks, and as a rule, this weekly regimen was repeated 50 times in patients with evidence of objective response or stable disease. In this series, complete response and partial response were achieved in 1 and 11 patients, respectively; however, the remaining 20 and 20 patients were diagnosed as showing stable disease and progressive disease, respectively. Of several parameters examined, presence of metastases at diagnosis and C-reactive protein (CRP) level were significantly associated with response to this combined therapy. The 1-, 3-, and 5-year cancer-specific survival rates of these 52 patients were 80.4%, 51.7%, and 38.8%, respectively. Furthermore, cancer-specific survival was significantly associated with performance status, presence of metastases at diagnosis, metastatic organ and CRP level on univariate analysis; however, only performance status and presence of metastases at diagnosis appeared to be independent predictors of cancer-specific death by multivariate analysis. Toxicities related to this therapy were generally mild and tolerable, limited to World Health Organization (WHO) grade 1 or 2 in the majority of patients. Collectively, these findings suggest that combined immunotherapy with IFN-alpha and low-dose IL-2 could achieve comparatively acceptable oncological outcomes in patients with metastatic RCC; however, other therapeutic options should be considered in patients with unfavorable performance status and/or those positive for metastatic diseases at diagnosis." @default.
• W1983391421 created "2016-06-24" @default.
• W1983391421 creator A5019547945 @default.
• W1983391421 creator A5041954417 @default.
• W1983391421 creator A5059104414 @default.
• W1983391421 creator A5076120482 @default.
• W1983391421 creator A5089760587 @default.
• W1983391421 date "2009-11-01" @default.
• W1983391421 modified "2023-10-18" @default.
• W1983391421 title "Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma" @default.
• W1983391421 cites W1987417042 @default.
• W1983391421 cites W2018333422 @default.
• W1983391421 cites W2022873097 @default.
• W1983391421 cites W2031063133 @default.
• W1983391421 cites W2034288843 @default.
• W1983391421 cites W2041881143 @default.
• W1983391421 cites W2071378220 @default.
• W1983391421 cites W2079506511 @default.
• W1983391421 cites W2081672131 @default.
• W1983391421 cites W2083040816 @default.
• W1983391421 cites W2085340970 @default.
• W1983391421 cites W2098136315 @default.
• W1983391421 cites W2106453307 @default.
• W1983391421 cites W2123914905 @default.
• W1983391421 cites W2138822094 @default.
• W1983391421 cites W2149456801 @default.
• W1983391421 cites W2171469612 @default.
• W1983391421 cites W2334694951 @default.
• W1983391421 cites W4229808435 @default.
• W1983391421 doi "https://doi.org/10.1016/j.urolonc.2008.07.023" @default.
• W1983391421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18818106" @default.
• W1983391421 hasPublicationYear "2009" @default.
• W1983391421 type Work @default.
• W1983391421 sameAs 1983391421 @default.
• W1983391421 citedByCount "27" @default.
• W1983391421 countsByYear W19833914212012 @default.
• W1983391421 countsByYear W19833914212013 @default.
• W1983391421 countsByYear W19833914212014 @default.
• W1983391421 countsByYear W19833914212015 @default.
• W1983391421 countsByYear W19833914212017 @default.
• W1983391421 countsByYear W19833914212022 @default.
• W1983391421 crossrefType "journal-article" @default.
• W1983391421 hasAuthorship W1983391421A5019547945 @default.
• W1983391421 hasAuthorship W1983391421A5041954417 @default.
• W1983391421 hasAuthorship W1983391421A5059104414 @default.
• W1983391421 hasAuthorship W1983391421A5076120482 @default.
• W1983391421 hasAuthorship W1983391421A5089760587 @default.
• W1983391421 hasConcept C121608353 @default.
• W1983391421 hasConcept C126322002 @default.
• W1983391421 hasConcept C141071460 @default.
• W1983391421 hasConcept C143998085 @default.
• W1983391421 hasConcept C144301174 @default.
• W1983391421 hasConcept C203014093 @default.
• W1983391421 hasConcept C2776178377 @default.
• W1983391421 hasConcept C2776907518 @default.
• W1983391421 hasConcept C2777472916 @default.
• W1983391421 hasConcept C2777701055 @default.
• W1983391421 hasConcept C2778822529 @default.
• W1983391421 hasConcept C2779134260 @default.
• W1983391421 hasConcept C2780091579 @default.
• W1983391421 hasConcept C2780227381 @default.
• W1983391421 hasConcept C2781068499 @default.
• W1983391421 hasConcept C2781413609 @default.
• W1983391421 hasConcept C2909179924 @default.
• W1983391421 hasConcept C38180746 @default.
• W1983391421 hasConcept C71924100 @default.
• W1983391421 hasConcept C90924648 @default.
• W1983391421 hasConceptScore W1983391421C121608353 @default.
• W1983391421 hasConceptScore W1983391421C126322002 @default.
• W1983391421 hasConceptScore W1983391421C141071460 @default.
• W1983391421 hasConceptScore W1983391421C143998085 @default.
• W1983391421 hasConceptScore W1983391421C144301174 @default.
• W1983391421 hasConceptScore W1983391421C203014093 @default.
• W1983391421 hasConceptScore W1983391421C2776178377 @default.
• W1983391421 hasConceptScore W1983391421C2776907518 @default.
• W1983391421 hasConceptScore W1983391421C2777472916 @default.
• W1983391421 hasConceptScore W1983391421C2777701055 @default.
• W1983391421 hasConceptScore W1983391421C2778822529 @default.
• W1983391421 hasConceptScore W1983391421C2779134260 @default.
• W1983391421 hasConceptScore W1983391421C2780091579 @default.
• W1983391421 hasConceptScore W1983391421C2780227381 @default.
• W1983391421 hasConceptScore W1983391421C2781068499 @default.
• W1983391421 hasConceptScore W1983391421C2781413609 @default.
• W1983391421 hasConceptScore W1983391421C2909179924 @default.
• W1983391421 hasConceptScore W1983391421C38180746 @default.
• W1983391421 hasConceptScore W1983391421C71924100 @default.
• W1983391421 hasConceptScore W1983391421C90924648 @default.
• W1983391421 hasIssue "6" @default.
• W1983391421 hasLocation W19833914211 @default.
• W1983391421 hasLocation W19833914212 @default.
• W1983391421 hasOpenAccess W1983391421 @default.
• W1983391421 hasPrimaryLocation W19833914211 @default.
• W1983391421 hasRelatedWork W1983391421 @default.
• W1983391421 hasRelatedWork W2014368823 @default.
• W1983391421 hasRelatedWork W2018333422 @default.
• W1983391421 hasRelatedWork W2045947905 @default.
• W1983391421 hasRelatedWork W2116661424 @default.
• W1983391421 hasRelatedWork W2148491024 @default.

• next